When combined with standard biomarkers (HbA1c, lipids, fasting insulin), genetic insights can enhance your provider's prior authorization narrative
Common Side Effects (Generally Mild): Temporary injection site reactions (redness, slight swelling) Mild fatigue initially (as metabolism adjusts) Occasional flushing or warmth Slight changes in appetite Contraindications and Precautions: Pregnancy or breastfeeding (insufficient safety data) Active cancer (theoretical concerns about growth pathways) Severe kidney or liver disease (requires monitoring) Hypoglycemia risk (monitor if on diabetes medications) Medical Monitoring: At The Lamkin Clinic, we monitor MOTS-C patients with: Baseline metabolic labs (glucose, HbA1c, insulin, lipids) Follow-up testing at 8-12 weeks Body composition analysis Assessment of symptoms and energy levels Adjustment of other medications as metabolism improves Important: MOTS-C should only be used under the guidance of a qualified healthcare provider experienced in peptide therapy
Dosing started at 0.6 mg per day and increased by weekly 0.6 mg increments to mitigate gastrointestinal side effects
Although many GLP1 RAs do not require dose adjustments based solely on eGFR, the absence of robust trial data in dialysis patients adds complexity to their use
Food and Drug Administration announced Ozempic's warning label would be updated to say it may be linked to a life-threatening intestinal blockage
However, as with many peptides, there is still a limited amount of research on the long-term effects of using AOD 9604, and much of the evidence comes from anecdotal user experiences
